{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T13:44:50Z","timestamp":1782135890661,"version":"3.54.5"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In a randomized clinical trial, pre-exposure prophylaxis (PrEP) with long-acting cabotegravir (CAB-LA) had a better bone safety profile than tenofovir disoproxil fumarate\u2013emtricitabine (TDF-FTC) over 105 weeks. For individuals with low bone mineral density or other fracture risk factors, CAB-LA PrEP should be considered over TDF-based PrEP.<\/jats:p>\n                  <jats:p>Clinical Trials Registration. \u00a0clinicaltrials.gov (NCT02720094).<\/jats:p>","DOI":"10.1093\/cid\/ciaf221","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T07:57:34Z","timestamp":1746518254000},"page":"983-986","source":"Crossref","is-referenced-by-count":2,"title":["Bone Changes With Long-Acting Cabotegravir or Tenofovir Disoproxil Fumarate\/Emtricitabine for HIV Prevention in Cisgender Men and Transgender Women: HPTN 083"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8599-278X","authenticated-orcid":false,"given":"Todd T","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Medicine, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F","family":"Arao","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Warsi","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nittaya","family":"Phanuphak","sequence":"additional","affiliation":[{"name":"Institute of HIV Research and Innovation , Bangkok ,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9753-0563","authenticated-orcid":false,"given":"Ricardo","family":"Vasconcelos","sequence":"additional","affiliation":[{"name":"Department of Infectious and Parasitic Diseases, University of Sao Paulo , Sao Paolo ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Temitope","family":"Oyedele","sequence":"additional","affiliation":[{"name":"Astra Zeneca , Gaithersburg, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip A","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Johns Hopkins University , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-2979","authenticated-orcid":false,"given":"Brett","family":"Hanscom","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center , Seattle, Washington ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F","family":"Rooney","sequence":"additional","affiliation":[{"name":"Gilead Sciences , Foster City, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R","family":"Rinehart","sequence":"additional","affiliation":[{"name":"ViiV Healthcare , Chapel Hill, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marybeth","family":"McCauley","sequence":"additional","affiliation":[{"name":"FHI 360 , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Grinsztejn","sequence":"additional","affiliation":[{"name":"Instituto Nacional de Infectologia Evandro Chagas-Fiocruz , Rio de Janeiro ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1442-714X","authenticated-orcid":false,"given":"Raphael J","family":"Landovitz","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California\u2013Los Angeles , Los Angeles, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"2025122403230876300_ciaf221-B1","doi-asserted-by":"crossref","first-page":"e048478","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"Murchu","year":"2022","journal-title":"BMJ Open"},{"key":"2025122403230876300_ciaf221-B2","doi-asserted-by":"crossref","first-page":"e23688","DOI":"10.1371\/journal.pone.0023688","article-title":"Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco","volume":"6","author":"Liu","year":"2011","journal-title":"PLoS One"},{"key":"2025122403230876300_ciaf221-B3","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/jac\/dkab400","article-title":"Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and\/or maraviroc and\/or emtricitabine in US men and women: HPTN 069\/ACTG A5305","volume":"77","author":"Brown","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2025122403230876300_ciaf221-B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/cid\/ciw765","article-title":"Decline in bone mass with tenofovir disoproxil fumarate\/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis","volume":"64","author":"Havens","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2025122403230876300_ciaf221-B5","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025122403230876300_ciaf221-B6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/QAI.0000000000001475","article-title":"Brief report: recovery of bone mineral density after discontinuation of tenofovir-based HIV pre-exposure prophylaxis","volume":"76","author":"Glidden","year":"2017","journal-title":"J Acquir Immune Defic Syndr (1999)"},{"key":"2025122403230876300_ciaf221-B7","volume-title":"Pre-exposure prophylaxis for the prevention of HIV infection: a systematic review for the U.S. Preventive Services Task Force","author":"Chou","year":"2023"},{"key":"2025122403230876300_ciaf221-B8","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1089\/aid.2018.0280","article-title":"Effect of vitamin D supplementation on bone turnover markers during HIV pre-exposure prophylaxis using tenofovir disoproxil fumarate-emtricitabine in men who have sex with men","volume":"35","author":"Nanayakkara","year":"2019","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2025122403230876300_ciaf221-B9","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu","year":"2021","journal-title":"Lancet HIV"},{"key":"2025122403230876300_ciaf221-B10","author":"Centers for Disease Control and Prevention"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf221\/63635542\/ciaf221.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/983\/63635542\/ciaf221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/983\/63635542\/ciaf221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:23:17Z","timestamp":1766564597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/5\/983\/8180179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":10,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,7,1]]},"published-print":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf221","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,7,1]]}}}